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ABSTRACT: A new, simple, precise, accurate and rapid high performance thin layer chromatographic 
method has been developed and validated for the estimation of ubidecarenone in bulk and in capsule 
formulation. The chromatographic separation was performed on aluminium TLC plates precoated with 
silica gel 60F254 as a stationary phase and methanol:water (7:3) as a mobile phase. Detection was per-
formed densitometrically in the absorbance mode at 280nm for the evaluation of chromatograms. The 
system has given well sharp peak of ubidecarenone (Rf=0.51±0.02). The linearity of the method was es-
tablished in the range of 1-6 ng/µL with correlation coefficient (r2) of 0.9995. The method was validated 
for precision, accuracy, robustness, ruggedness, LOD, and LOQ as per ICH guidelines. The limit of detec-
tion was found to be 0.0392 ng/µL, whereas the limit of quantitation was found to be 0.1189 ng/µL. The 
percentage label claim for ubidecarenone in the capsule formulation was found to be 99.96±0.4703. The 
accuracy of the method was confirmed by recovery studies. The percentage recovery was found to be in 
the range of 100.10-101.45% for ubidecarenone. The % RSD value was found to be less than 2. The low 
%RSD value indicates that there is no interference due to excipients used in the formulation. Hence, the 
developed method was found to be simple, precise, accurate, and rapid for the analysis of ubidecarenone 
in bulk and pharmaceutical formulation and it can be effectively applied for the quality control analysis 
of ubidecarenone in bulk and pharmaceutical formulation.
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1. Introduction
Ubidecarenone (UBD) (coenzyme Q10, CoQ10, 
coenzyme Q), is chemically 2,5-cyclohexadiene-1,4-
dione,2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-
3 , 7 , 1 1 , 1 5 , 1 9 , 2 3 , 2 7 , 3 1 , 3 5 , 3 9 - d e c a m e t h
yl2,6,10,14,18,22,26,30,34,38-tetracontade–
caenyl]-5,6-dimethoxy-3-methyl. It is official in 
USP [1], BP [2] and EP [3]. It is shown in Figure 1. 
Ubidecarenone is an oil-soluble, vitamin-like sub-
stance present in all eukaryotic cells, primarily in 
the mitochondria are family of compounds that 
differ in the number of isoprenoid subunits of 
the sidechains. Ubidecarenone is an important 
component in the electron transport chain es-
sential for aerobic cellular respiration, generating 
chemical energy in the form of ATP [4 - 5]. To per-
form its role as an antioxidant and component in 
the electron transport chain, ubidecarenone can 
exist as both reduced and oxidized form. The re-
duced form of ubidecarenone molecule can easily 
donate one or both electrons and act as an anti-
oxidant [6]. One of the most important function 
of ubidecarenone is the inhibition of lipid per-
oxidation through lipid peroxyl radicals (LOO) 
inhibition. Ubidecarenone is essential to keep 
the cardiovascular system in a healthy condition. 
Heart failure is usually accompanied by the de-
ficiency of CoQ10. The plasma concentration of 
CoQ10 is considered as a marker of mortality in 
chronic heart failure and the long-term prognosis 
of chronic heart failure [7]. It is used for the treat-
ment of migraine [8] and cancer [9- 11]. Studies 
have also revealed that the level of coenzyme 
Q10is less in diseased gum tissue compared with 
healthy gum tissue [12,13] improving the gingival 
health, immune response in gum tissues, and re-
versing the diseased gum conditions [14-16] im-
proves the periodontitis and gingivitis conditions 
[17] help in the reduction of radiation damage to 
the animals’ blood [18].
Several HPLC methods were developed for 
the estimation of CoQ10 in human plasma, raw 
materials, and dietary supplements [19-24]. 
Analysis of an inclusion complex of CoQ10 with 
β-cyclodextrin was performed by TLC [25]. A 
sensitive and selective analysis of CoQ10 in hu-
man serum was also achieved by negative APCI 
LC-MS [26]. CoQ10 was analyzed in pharmaceuti-
cal formulations using FT-IR spectrophotometric 
method [27]. CoQ10 stability in pediatric liquid 
oral dosage formulations and its bioequivalence 
studies of two marketed formulations of coen-
zyme Q10 in beagle dogs has been reported [28-
29]. HPLC method [30-35] and UV spectroscopic 
method [36-37] also reported for the estimation 
of ubidecarenone.
To the best of our knowledge, no reports on 
densitometric HPTLC analytical methods for the 
analysis of ubidecarenone in bulk and in capsule 
formulation have been mentioned in the litera-
ture. The objective of this study was, therefore, 
Figure 1. Molecular structure of ubidecarenone
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to develope a simple, accurate, selective, precise, 
sensitive, robust, and stability-indicating densito-
metric HPTLC method for the quantitative deter-
mination of ubidecarenone in bulk and in capsule 
formulation.
2. Materials and methods
2.1. Chemicals
Analytical grade ethanol, acetone, methanol, 
acetonitrile (Loba Chemie India Limited, Mum-
bai, India) were used. UBD working standard was 
supplied by Sai Mirra Innopharm Private Limited, 
Chennai. The working standard was certified to 
contain 99.55% of UBD. Ubi Q300 capsule con-
taining 300 mg of UBD was procured from the 
local market.
2.2. Instrumentation and chromatographic con-
ditions
Camag HPTLC apparatus consisting of Lino-
mat V sample applicator (Camag, Muttenz, Swit-
zerland), 100 µL syringe (Hamilton–Bonaduz 
Schweiz, Camag, Switzerland), TLC scanner III 
(Camag, Muttenz, Switzerland) WinCATS version 
1.4.0 software (Camag, Muttenz, Switzerland) 
were used in the study. Chromatography was per-
formed on Merck silicagel 60 F254 precoated TLC 
plates (20 cm x 20 cm with 200 µm thickness). 
Saturation pad (Camag, Muttenz, Switzerland) 
was used for saturating development chambers. 
Samples were applied as bands under a stream 
of nitrogen using the µL syringe. Ascending deve–
lopment to a distance of 7 cm was performed in a 
30 minutes presaturated 20x20 cm twin trough 
TLC developing chamber (Camag). Developed 
plates were dried using hair drier. Densitometric 
scanning and quantitative evaluation were per-
formed using the TLC scanner and Win CATS ver-
sion 1.4.0 software respectively.
2.3. Selection of mobile phase
The following solvent mixtures were se-
lected for the method development are 
acetonitrile:water (5:5), methanol:ethylacetate 
(5:5), methanol:acetonitrile (5:5), methanol: 
water (5:5), methanol:water (7:3). From that, 
methanol:water (7:3) was selected as a mobile 
phase. Because, the drug eluted with good peak.
2.4. Preparation of standard stock solution
The standard stock solution of UBD was pre-
pared by dissolving 10 mg of UBD in 10 mL of 
mobile phase to get a concentration of 1 mg/mL.
2.5. Selection of wavelength
One mL of the standard stock solution was di-
luted to get the concentration of 10 µg/mL. The 
solution was scanned over the wavelength range 
of 200-400 nm and the spectrum was obtained. 
From that spectrum, the λmax was found to be 280 
nm and this was selected as a detection wave-
length. 
2.6. Preparation of calibration curve
0.1 mL to 0.6 mL of standard stock solution 
was pipetted out in to a series of 100 mL volume–
tric flasks. The solutions were diluted with mo-
bile phase to get the concentration range of 1-6 
ng/µL of UBD. The solutions were applied on the 
TLC plate. The chromatogram was developed and 
scanned at 280 nm. The peak areas of the respec-
tive chromatograms were recorded and the cali-
bration graph was constructed by plotting peak 
area vs concentration. The regression equation 
was calculated. The procedure was repeated for 
six times.
2.7. Quantification of capsule formulation
Twenty capsules were weighed accurately 
and the average weight of each capsule was de-
termined. The mixed content of the capsule pow-
der equivalent to 10 mg of UDB was weighed and 
transferred into a 100 mL volumetric flask. The 
powder was dissolved with mobile phase, made 
up to 100 mL with the same and filtered. From 
this solution, 0.3 mL was diluted to 100 mL with 
mobile phase to get a concentration of 3 ng/µL. 
Six spots were placed on the plate and the chro-
matograms were recorded. From the peak area, 
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the amount of the drug was calculated. The pro-
cedure was repeated for six times.
2.8. Recovery studies
2.8.1. Preparation of ubidecarenone raw mate-
rial stock solution
100 mg of UBD was accurately weighed, dis-
solved with mobile phase and the volume was 
made up to 100 mL. The solution contains 1 mg/
mL.
2.8.2. Procedure
The recovery study was done by adding a 
known concentration of raw material stock solu-
tion of UBD to the pre-analyzed formulation. The 
capsule powder equivalent to 100 mg of UDB was 
weighed into three separate 100 mL volumetric 
flasks and dissolved with mobile phase. To this 0.2 
mL, 0.3 mL, and 0.4 mL of UBD raw material stock 
solution were added. The solution was made up 
to 100 mL and filtered. The clear solution was 
spotted from each flask and the chromatogram 
was recorded. The procedure was repeated for 
three times and the amount of drug recovered 
was calculated.
2.8.3. Method validation
The method was validated in compliance with 
ICH guidelines [38]. The following parameters 
were validated.
2.8.4. Specificity
Specificity of the method was evaluated to en-
sure that there was no interference from the ex-
cipients present in the formulation. The placebo, 
sample, and standard solutions were applied 
on the TLC plates separately and the chromato-
grams were recorded. The Rf value of the sample 
chromatogram was compared with its respective 
standard.
2.8.5. Linearity and range
Linearity of the method was assessed by ana-
lyzing the standard stock solution of UBD at six 
different concentrations. UBD was linear in the 
concentration range of 1-6 ng/µL at 280 nm. The 
calibration plot was constructed by plotting peak 
area against corresponding concentration of 
drug. The linear regression equation was deter-
mined by the method of least squares. The range 
was determined as 80-120% of the assay concen-
tration.
2.8.6. Sensitivity
Limit of Detection (LOD) and Limit of Quan-
titation (LOQ) were computed to establish the 
method sensitivity. For determination of LOD 
and LOQ, serial standard solutions of UBD (n = 6) 
were applied in six replicates. By observing peak 
area, calibration curve was constructed. LOD and 
LOQ were calculated by using LOD = 3.3 σ/S and 
10 σ/S, where σ is standard deviation of y inter-
cept in regression equation and S is slope of the 
calibration curve.
2.8.7. Precision
The precision of the method was considered 
at two levels, repeatability and intermediate pre-
cision. The repeatability study was confirmed by 
analysis of formulation was repeated for six times 
with the same concentration. The intermediates 
studies were demonstrated by intraday and in-
terday studies. In this, the analysis of formulation 
was repeated for three times on the same day and 
on three successive days. The amount of the drug 
was determined. The precision of the method was 
expressed as percentage relative standard devia-
tion (% RSD).
2.8.8. Accuracy
To confirm the accuracy of the method, reco–
very experiments were carried out by the stan-
dard addition technique. It was carried out by 
adding known amount of standard UBD to the 
preanalysed formulation corresponding in three 
concentration levels (80, 100, and 120%) of the 
working concentration with excipients and to the 
working standard solution.
2.8.9. Robustness
Robustness of the method was assessed by 
making small, deliberate changes in the opti-
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 Figure 2. UV spectrum of ubidecarenone in mobile phase by HPTLC
mized chromatographic conditions like mobile 
phase composition, detection wavelength, satu-
ration time of development chamber, time from 
spotting to development and time from develop-
ment to scanning were applied. The Rf value, peak 
area and %RSD were calculated.
2.8.10. Ruggedness
The ruggedness of the proposed method was 
performed by the analysis of sample under a va-
riety of test conditions such as different analysts, 
different instruments and different laboratories. 
The %RSD was calculated.
3. Results and discussion
3.1. Method development and optimization
In this study, different mixtures of various sol-
vents were tried and the composition of mobile 
phase with a chromatographic result having ac-
ceptable and reproducible Rf value was selected. 
The detection wavelength was selected based on 
maximum absorption with optimal sensitivity. 
The ubidecarenone solution was scanned over the 
wavelength range 200-400 nm and the spectrum 
was recorded. Ubidecarenone shows maximum 
absorption at 280 nm. Hence, it was selected as a 
detection wavelength. It is shown in Figure 2.
Initially, two different mixtures of solvents tried 
were acetonitrile:water (5:5) and methanol:ethyl 
acetate (5:5). Both compositions resulted in 
broadened peaks with the Rf values of 0.39 and 
0.25, respectively. In methanol:acetonitrile (5:5), 
the peak was observed for UBD. But the intensity 
of the peak was decreased due to degradation. 
Then methanol:water (5:5) was tried. It was good 
with some unwanted peaks. So, the mobile phase 
was tried in different proportions i.e. 6:4, 7:3, and 
8:2. Finally, methanol:water in the ratio of (7:3) 
had given the well defined sharp peak without 
the unwanted peaks. Hence this mobile phase 
was selected for further analysis. The Rf value of 
UBD was found to be Rf =0.51. 
After the many trials, the optimized condition that 
offered best peak (as shown in Figure 3) was on a 
precoated silica gel plates using methanol:water 
(7:3) as mobile phase, 10 mL per single run. 
Length of chromatogram was 7 cm with cham-
ber saturation time of 30 minutes. Detection was 
made at 280 nm.
3.2. Method validation
3.2.1. Specificity
The specificity is the ability to assess unequi–
vocally the analyte in the presence of components 
such as impurities, degradation products, ob-
tained experimentally or by inducing their forma-
tion [39]. In this study, specificity of the method 
was checked by comparing the chromatograms 
obtained for pure UBD, the placebo and the sam-
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Figure 4. Calibration curve of ubidecarenone
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ple. It was proved by comparing the Rf value of 
the sample chromatogram with its standard. 
There is no interference has been observed bet–
ween the peaks of placebo, sample and standard. 
Therefore, the developed method was found to be 
specific. 
3.2.2. Sensitivity
Sensitivity of the method was confirmed by 
calculating the limit of detection and limit of 
quantitation. The LOD and LOQ values for UBD 
were found to be 0.0392 ng/mL and 0.1189 ng/
mL, respectively. This indicates that the sensiti–
vity of the method was confirmed.
3.2.3. Linearity
The developed method was found to be linear 
in the concentration range of 1-6 ng/µL. The cor-
relation coefficient (r2) was found to be 0.9995, 
which indicates that the linear regression data for 
the calibration curve shows good linearity with 
concentration. The calibration curve was shown 
in Figure 4. The optical characteristics data are 
shown in Table 1.
3.2.4. Precision
Repeatability and intermediate precision of 
the developed method were expressed in terms 
of percentage relative standard deviation (%RSD) 
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Parameters Values* 
max (nm) 280 
Beer’s law limit (ng/L) 1-6 
Correlation coefficient (r) 0.9995 
Regression equation (y = mx + c) Y = 1775.55x +160.4809 
Slope (m) 1775.55 
Intercept (c) 160.4809 
LOD (g/mL) 0.0392 
LOQ (g/mL) 0.1189 
Standard error 0.1189 
*Mean of six observations 
Table 1. Optical characteristics data
Table 2. Analysis of formulation by HPTLC method
Table 3. Intraday and interday precision study
of the peak area. Repeatability of the method was 
confirmed by the repeated analysis of formula-
tion for six times. The percentage purity of UBD 
in formulation was found to be 99.96%. The % 
RSD value was calculated and it was found to be 
0.4705. The results of the analysis are shown in 
Table 2. The intermediate precision was done 
by intraday and interday analysis. The analysis 
of formulation was repeated three times on the 





SD % RSD 
Intra day Inter day Intra day Inter day Intra day Inter day 
1 300 99.20 99.31 0.1896 0.1240 0.1906 0.1248 
2 300 99.23 99.37     
3 300 99.19 99.34     
Mean  99.18 99.94     











Mean SD % RSD SE CI 
1 300 300.63 100.21 99.96 0.4703 0.4705 0.1920 99.18 
2 299.41 99.80     to 
3 302.41 100.80     100.73 
4 298.86 99.62      
5 299.38 99.79      
6 298.65 99.55      
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Table 4. Recovery analysis of formulation
Table 5. Robustness study by HPTLC method
Parameters Change in 
chromatographic 
condition 
Rf Value* Peak area* %RSD 
























*Mean of six observations of six replicates 
 
Table 6. Robustness study by HPTLC method
No Category Labelled amount 
(mg/tablet) 
Mean* SD %RSD 
1 ANALYST I 300 99.60 0.2305 0.2314 
2 ANALYST II 300 99.40 0.1176 0.1183 
   *Mean of six observations 
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value for the intraday and interday analysis of 
UBD was found to be 0.1906 and 0.1248 respec-
tively. This is shown in Table 3. The % RSD values 
for repeatability and intermediate precision were 
found to be less than 2%. This indicated that the 
method was found to be precise.
3.2.5. Accuracy
Accuracy of the method was confirmed by 
recovery studies. The percentage recovery was 
found to be in the range of 100.10% to 101.45%. 
The % RSD was found to be 0.4928. The low % 
RSD indicates that there is no significant interfe–
rence due to excipients used in formulation. This 
ensures that the method is more accurate. The re-
sults of the recovery studies are shown in Table 4.
3.2.6. Robustness
Robustness of the method was performed by 
making small deliberate changes in described 
chromatographic conditions. No significant dif-










































































    Mean  100.88   
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area. The % RSD was found to be 0.8792. The low 
% RSD indicates that the method is robust. The 
results are shown in Table 5. 
3.2.7. Ruggedness
Ruggedness of the method was performed by 
the analysis of formulation with the help of two 
different analysts. The % RSD was found to be 
0.2314 and 0.1183, respectively. The results are 
shown in Table 6.
3.2.8. Analysis of capsule formulation
The amount of the drug was found to be 99.96 
± 0.4703. The % RSD was found to be 0.4705. The 
low % RSD indicates the suitability of the me–
thod for the analysis of UBD in the pharmaceuti-
cal dosage form.
3.2.9. Comparision of the developed method 
with reported methods
When comparing the proposed method with 
the reported methods, there are HPLC and UV 
spectroscopic methods were reported. The con-
centration range used for the linearity was very 
high for both HPLC (60-180 µg/mL) and UV 
spectroscopic method (10-80 µg/mL), but in the 
proposed method was 1-6 ng/µL. The LOD and 
LOQ were very low for the proposed method and 
hence the developed method was considered as 
sensitive. Even though UV spectroscopic method 
is simple, the method lack in sensitivity. Hence 
the developed method was found to be sensitive 
and accurate when compared to the reported 
methods.
4. Conclusion
A new high performance thin layer chromato-
graphic method (HPTLC) has been developed 
and validated for determination of UBD in bulk 
and in capsule formulation. Reliable HPLC analy-
sis of this drug can be performed on TLC plate coated 
with silica gel 60 F254. The mobile phase was 
methanol:water (7:3). Densitometry analysis was 
performed at 280 nm. The method is simple, sen-
sitive (LOD and LOQ were 0.0392 and 0.1189 ng/
mL, respectively), precise (RSD ± 2%) and linear 
over the range 1-6 ng/µL with r2 value of 0.9995. 
The developed HPTLC method was found suitable 
for determination of UBD in capsule formulation 
without any interference from the excipients. 
Therefore, the developed HPTLC method offers 
many advantages in terms of cost, reduced analy-
sis run time, simplicity, precision, accuracy, ro-
bustness etc. Thus, the proposed HPTLC method 
was effectively utilized for the routine quality 
control analysis of ubidecarenone in bulk and in 
capsule formulation.
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